Evidence basis: The effect of safinamide, with a dual mechanism of action as a partial NMDA-receptor antagonist and MAO-B-inhibitor, on the frequency and severity of dyskinesias was examined in 2 studies. This evidence concerns the gene MAOB and drug-induced dyskinesia.